Key clinical point:.
Major finding: Compared with chemotherapy alone, chemotherapy plus atezolizumab prolonged median progression-free survival from 5.6 to 6.3 months (hazard ratio, 0.71; P = .0001).
Study details: A phase 3 randomized, controlled trial among 1,021 all-comer (PD-L1–unselected), chemotherapy-naïve patients with stage IV squamous NSCLC (IMpower131 trial).
Disclosures: Dr. Jotte disclosed that he is on the speakers’ bureau for Bristol-Myers Squibb, and that he receives travel, accommodations, and/or expenses, as well as honoraria from Bristol-Myers Squibb. The study received funding from F. Hoffmann-La Roche Ltd.
Source: Jotte et al. ASCO 2018 Abstract LBA9000.
Jotte et al. ASCO 2018 Abstract LBA9000.
This Week's Must Reads
Healthcare.gov open enrollment picks up in Week 2, Weekly enrollment snapshot on CMS.gov
Trump administration takes contradictory actions on ACA, A press statement issued on CMS.gov.
Doctors raise concerns about administration's Part B drug plan, A CMS Fact Sheet on the ANPRM International Pricing Index Model for Medicare Part B Drugs
CMS rescinds a proposal to blend E/M payments for now , 2019 Physician Fee Schedule
Guideline authors inconsistently disclose conflicts, Combs T et al. JAMA Intern Med. 2018 Oct 29. doi: 10.1001/jamainternmed.2018.4730. Khan R et al. JAMA Intern Med. 2018 Oct 29. doi: 10.1001/jamainternmed.2018.5106
Must Reads in Lung Cancer
Prophylactic cranial irradiation boosts OS in advanced NSCLC , Arrieta O et al. WCLC 2018, Abstract MA08.02.
Nivolumab safe and effective for cancer patients with HIV, Gobert et al. ESMO 2018, Abstract 1213P_PR.
CT scans cut lung cancer deaths, A presentation at the World Conference on Lung Cancer
Baseline steroid use may decrease efficacy of checkpoint inhibitors, Arbour KC et al. J Clin Oncol. 2018 Aug 20. doi: 10.1200/JCO.2018.79.0006.
NSCLC: Capmatinib plus gefitinib overcomes EGFR resistance , Wu et al. J Clin Oncol. 2018 Aug 29. doi: 10.1200/JCO.2018.77.7326.